Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 6/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.72 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | RXRB | P28702 | 1/20 | 0.60 |
| ▸ | RXRG | P48443 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280198 | 1.00 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL12872352 | 1.00 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL12292033 | 0.89 | POLA1 (0.81) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL7767289 | 0.89 | POLA1 (0.81) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL19770990 | 0.89 | POLA1 (0.81) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL24177920 | 0.89 | POLA1 (0.81) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL19786219 | 0.89 | POLA1 (0.81) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL6312574 | 0.88 | NR1H2 (0.82) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL6312566 | 0.88 | NR1H2 (0.82) | POLA1NR1H2NR1H3CYP2C9TSHR | |
| SCHEMBL20560979 | 0.85 | POLA1 (0.73) | POLA1NR1H2NR1H3CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230139-B2 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X BIOTECHNOLOGIES (CA) | 2007-06-12 | — | — | US | disclosed |
| US-7217844-B2 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X BIOTECHNOLOGIES (CA) | 2007-05-15 | — | — | US | disclosed |
| US-20050070540-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| US-20050032802-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X BIOTECHNOLOGIES INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070540-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | CYP51A1, ERG28, BAD | POLA1 2618/4885NR1H2 869/4885NR1H3 824/4885 |
| US-20050032802-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | CYP51A1, ERG28, BAD | POLA1 2618/4885NR1H2 869/4885NR1H3 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.